Bone Graft Materials/DBM

Orthobiologics Face Pressure from Lack of Clinical Evidence

Orthobiologics Face Pressure from Lack of Clinical Evidence
In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface
With the acquisitions of Parcus Medical and Arthrosurface, Anika looks ready to complete a major step in its five-year strategic plan to become a leader in joint preservation and restoration.

Member-Only Content


FDA 510(k) Recap: Spinal Devices and Technologies from 1H19

With the NASS 2019 Annual Meeting approaching, it's an ideal time to revisit spine products that have gained FDA 510(k) clearance in the first half of the year. This round-up shares another entrant into the sacroiliac joint treatment arena, an implant company's first clearance for an enabling technology and additional details about some lesser-known companies to watch.

Royal Biologics Gains Funding

Royal Biologics, developer of products for regenerative medicine, received funding to support employee onboarding, operational growth, product development and acquisitions. 

NuVasive Launches New Orthobiologic Products

NuVasive commenced U.S. launch of three new biologic products for spine, including traditional bone allograft, an amniotic membrane and new formats in the Propel Demineralized Bone Matrix line. 

Cerapedics Closes $22MM Financing

Cerapedics completed a US $22MM financing. Proceeds will support commercialization and a U.S. lumbar trial of i-FACTOR bone graft.

Artoss Completes $1MM Funding Round

Artoss completed a US $1MM funding round. Proceeds will support development of new NanoBone® bone graft products for the U.S. market, regulatory requirements and commercialization.

Pre-clinical Study Results: Multipotent Adult Progenitor Cells on an Allograft Scaffold

Pre-clinical studies suggest that multipotent adult progenitor cells (MAPCs), such as the technology used in RTI Surgical's map3® Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. mesenchymal stem cells in vitro.

Preclinical Study Validates Science Behind AlloSource AlloStem Cellular Bone Allograft

Preclinical data on adipose-derived mesenchymal stem cells in a rat model, using technology similar to AlloSource's AlloStem® Cellular Bone Allograft process, showed bone formation within a critical-sized defect in all study subjects.

Bioventus New Product Launches

At AAOS 2016, Bioventus is introducing the CellXtract™ novel cell and bone marrow extraction tool and SIGNAFUSE™, a bioactive bone graft putty. 

MiMedx to Acquire Stability Biologics

MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock. Stability Biologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16.